socalTECH

APRIL 24, 2015

We caught up with serial entrepreneur Derrick Oien , who is CEO of the company, to learn more. Tell us a little bit about this new startup? Derrick Oien: We started Sportstream three years ago. It's actually nice that there is a shortage of capital for sports startups. I was at MP3.com, com, and then Intercasting.

Media 100

Media Startup Avalon Social Media 100

Xconomy

AUGUST 17, 2016

and San Diego’s Avalon Ventures. Stengone said the new funding also will help the company evaluate the use of AVB-620 in other types of cancer surgery, to advance new cancer drugs that rely on Avelas’ proprietary technology, and to expand the company’s current roster of “seven employees and an army of consultants.”.

Avalon 40

Avalon San Diego Study Invest 40

Tech Zulu Event

DECEMBER 6, 2013

The Connected Car , where automotive and technology (outside of vehicle performance and earth saving “greenness”) collide. It’s something of a sci-fi fantasy scenario: Driverless cars that show up at the touch of a button. You feel conflicted when you start to see ads. ” THE CAR AS A PRIVATE SPACE.

Advertising 97

Advertising Startup Marketing Mobile 97

Xconomy

OCTOBER 30, 2016

Plug and Play San Diego, established in 2013 as a satellite of the Sunnyvale, CA-based incubator, has funneled 15 local startups through the Silicon Valley program after providing some coaching and other services in San Diego. The other partners are Edward Adato and Daniel Schwarzblat.).

San Diego 40

San Diego Incubator Avalon Mentor 40

Xconomy

JULY 19, 2016

Synthorx, the San Diego synthetic biology startup that expanded the number of DNA base pairs with two synthetic nucleotides, said today it has raised $10 million in a Series B financing round led by RA Capital Management, the Boston life sciences hedge fund. Existing investors Avalon Ventures and Correlation Ventures joined in the round.

San Diego 40

San Diego Avalon Research Examples 40

Xconomy

APRIL 30, 2018

After demonstrating in 2016 how its synthetic biology technology could produce new biologic drugs , San Diego’s Synthorx today revealed that its lead drug candidate is an improved version of interleukin-2, an anti-cancer drug of intense commercial interest in the 1980s.

Technology 78

Technology Venture Capital San Diego Avalon 78

Xconomy

MAY 2, 2017

This is the direction we’re headed, according to Larry Smarr, founding director of the California Institute of Telecommunications & Information Technology at UC San Diego.

San Diego 63

San Diego Technical Review Software Review Networking 63

Xconomy

MARCH 23, 2017

Xconomy is convening life sciences and technology founders, executives, investors, and entrepreneurs for an afternoon of fireside chats and solo talks at Human Impact of Innovation. What are the emerging opportunities for investors and executives on these topics, and what role will San Diego play in the advancement of these technologies?

San Diego 52

San Diego Entrepreneur Technology Avalon 52

Xconomy

JULY 10, 2016

Larry’s diagnosis was cancer with a big C: “I have stage 4 pancreatic cancer and have been on chemo since June with some ups and downs,” he wrote in mid-March. He found he didn’t enjoy being a traditional VC gatekeeper who said “yes” or “no” to startup pitches, according to his wife, Diane. “He They had a lot of fun.”.

San Diego 40

San Diego Startup Avalon Venture Capital 40

Xconomy

AUGUST 31, 2016

In 2009, Tsien and Kevin Kinsella of Avalon Ventures founded San Diego’s Avelas Biosciences to develop fluorescent proteins that change color in the presence of cancer cells. In the statement released by UC San Diego, chancellor Pradeep Khosla said, every honor Tsien received was “justly deserved, and always received with humility.”.

San Diego 72

San Diego UCSD Avalon Study 72

Xconomy

SEPTEMBER 30, 2016

. —Caribou Biosciences president, CEO and co-founder Rachel Hurwitz spoke at the University of Texas Health Science Center at San Antonio about the many challenges she faced trying to form Caribou , one of a group of companies using CRISPR-Cas9 gene editing technology. Phase 3 trials should start next year.

Avalon 40

Avalon Thousand Oaks Study Startup 40